Checkpoint Inhibitors: Global Markets

Nov 2018| PHM185A| BCC Publishing

Report Highlights

The global checkpoint inhibitors market should reach $29.3 billion by 2023 from $14.9 billion in 2018 at a compound annual growth rate (CAGR) of 14.4% for the period of 2018-2023.

Report Includes

  • 21 data tables and 43 additional tables
  • An overview of the global market for checkpoint inhibitors
  • Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs
  • Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape
  • Insight into the FDA-approved treatments and numerous pipeline products targeting infectious disease treatments, including the novel coronavirus outbreak and its antibody-based clinical program REGN 3048-3051 (antibody to Middle Eastern Respiratory Coronavirus MERS-CoV infection)
  • Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRPα agents
  • Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro Inc., and Xencor

Report Scope

This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3, and CD47/SIRPα. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins, and chimeric antigen receptor (CAR) T cells.

Analyst Credentials

Dr. Cheryl L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C. L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter Name Pages Price Member Price
Full Report: Checkpoint Inhibitors: Global Markets 138 $2,500 Free
Chapter- 1: Introduction8Free DownloadFree
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Immuno-Oncology Market and Checkpoint Market Statistics13$236Free
Chapter- 4: PD-1/PD-L1 Agents43$779Free
Chapter- 5: CTLA-410$181Free
Chapter- 6: IDO-19$163Free
Chapter- 7: LAG-312$217Free
Chapter- 8: TIM-1,39$163Free
Chapter- 9: CD47/SIRPa12$217Free
Chapter- 10: Company Profiles11$199Free
Chapter- 11: Glossary of Terms1$18Free
Chapter- 12: Sources8$145Free
Checkpoint Inhibitors: Global Markets

Single User License: $2500

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report